References
Achord, D. T., Brot, F. E., & Sly, W. S. (1977). Inhibition of the rat
clearance system for agalacto-orosomucoid by yeast mannans and by
mannose. Biochem Biophys Res Commun, 77 (1), 409-415.
doi:10.1016/s0006-291x(77)80213-1
Barry, C. S., Cocinero, E. J., Carcabal, P., Gamblin, D. P.,
Stanca-Kaposta, E. C., Remmert, S. M., . . . Davis, B. G. (2013).
’Naked’ and hydrated conformers of the conserved core pentasaccharide of
N-linked glycoproteins and its building blocks. J Am Chem Soc,
135 (45), 16895-16903. doi:10.1021/ja4056678
Becerra-Arteaga, A., & Shuler, M. L. (2007). Influence of culture
medium supplementation of tobacco NT1 cell suspension cultures on the
N-glycosylation of human secreted alkaline phosphatase. Biotechnol
Bioeng, 97 (6), 1585-1593. doi:10.1002/bit.21344
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M.,
Foster, G. R., & Stark, G. R. (2007). Interferons at age 50: past,
current and future impact on biomedicine. Nat Rev Drug Discov,
6 (12), 975-990. doi:10.1038/nrd2422
Borys, M. C., Dalal, N. G., Abu-Absi, N. R., Khattak, S. F., Jing, Y.,
Xing, Z., & Li, Z. J. (2010). Effects of culture conditions on
N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion
protein produced in CHO cells. Biotechnol Bioeng, 105 (6),
1048-1057. doi:10.1002/bit.22644
Campbell, M. P., Royle, L., Radcliffe, C. M., Dwek, R. A., & Rudd, P.
M. (2008). GlycoBase and autoGU: tools for HPLC-based glycan analysis.Bioinformatics, 24 (9), 1214-1216.
doi:10.1093/bioinformatics/btn090
Castro-Borrero, W., Graves, D., Frohman, T. C., Flores, A. B., Hardeman,
P., Logan, D., . . . Frohman, E. M. (2012). Current and emerging
therapies in multiple sclerosis: a systematic review. Ther Adv
Neurol Disord, 5 (4), 205-220. doi:10.1177/1756285612450936
Chen, C., Wu, N., & Watson, C. (2018). Multiple sclerosis patients who
are stable on interferon therapy show better outcomes when staying on
same therapy than patients who switch to another interferon.Clinicoecon Outcomes Res, 10 , 723-730. doi:10.2147/CEOR.S163907
Diebold, M., & Derfuss, T. (2016). Immunological treatment of multiple
sclerosis. Semin Hematol, 53 Suppl 1 , S54-57.
doi:10.1053/j.seminhematol.2016.04.016
Dobryszycka, W., & Kukral, J. C. (1970). Metabolic studies on sialic
acid-free haptoglobin. Arch Immunol Ther Exp (Warsz), 18 (5),
527-536.
Dumitrescu, L., Constantinescu, C. S., & Tanasescu, R. (2018). Recent
developments in interferon-based therapies for multiple sclerosis.Expert Opin Biol Ther, 18 (6), 665-680.
doi:10.1080/14712598.2018.1462793
Engel, N., Weiss, V. U., Wenz, C., Rufer, A., Kratzmeier, M., Gluck, S.,
. . . Allmaier, G. (2015). Challenges of glycoprotein analysis by
microchip capillary gel electrophoresis. Electrophoresis, 36 (15),
1754-1758. doi:10.1002/elps.201400510
Eon-Duval, A., Broly, H., & Gleixner, R. (2012). Quality attributes of
recombinant therapeutic proteins: an assessment of impact on safety and
efficacy as part of a quality by design development approach.Biotechnol Prog, 28 (3), 608-622. doi:10.1002/btpr.1548
Gasperini, C., & Ruggieri, S. (2011). Emerging oral drugs for
relapsing-remitting multiple sclerosis. Expert Opin Emerg Drugs,
16 (4), 697-712. doi:10.1517/14728214.2011.642861
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A.
(2010). Implications of the presence of N-glycolylneuraminic acid in
recombinant therapeutic glycoproteins. Nat Biotechnol, 28 (8),
863-867. doi:10.1038/nbt.1651
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012).
Production platforms for biotherapeutic glycoproteins. Occurrence,
impact, and challenges of non-human sialylation. Biotechnol Genet
Eng Rev, 28 , 147-175.
Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., Halper, J., Likosky,
W. H., Lublin, F. D., . . . the, M. S. C. f. C. P. G. (2002). Disease
modifying therapies in multiple sclerosis: report of the Therapeutics
and Technology Assessment Subcommittee of the American Academy of
Neurology and the MS Council for Clinical Practice Guidelines.Neurology, 58 (2), 169-178. doi:10.1212/wnl.58.2.169
Grossberg, S. E., Oger, J., Grossberg, L. D., Gehchan, A., & Klein, J.
P. (2011). Frequency and magnitude of interferon beta neutralizing
antibodies in the evaluation of interferon beta immunogenicity in
patients with multiple sclerosis. J Interferon Cytokine Res,
31 (3), 337-344. doi:10.1089/jir.2010.0038
Hartung, H. P., Munschauer, F., 3rd, & Schellekens, H. (2005).
Significance of neutralizing antibodies to interferon beta during
treatment of multiple sclerosis: expert opinions based on the
Proceedings of an International Consensus Conference. Eur J
Neurol, 12 (8), 588-601. doi:10.1111/j.1468-1331.2005.01104.x
Hokke, C. H., Bergwerff, A. A., van Dedem, G. W., van Oostrum, J.,
Kamerling, J. P., & Vliegenthart, J. F. (1990). Sialylated carbohydrate
chains of recombinant human glycoproteins expressed in Chinese hamster
ovary cells contain traces of N-glycolylneuraminic acid. FEBS
Lett, 275 (1-2), 9-14. doi:10.1016/0014-5793(90)81427-p
Hossler, P., Khattak, S. F., & Li, Z. J. (2009). Optimal and consistent
protein glycosylation in mammalian cell culture. Glycobiology,
19 (9), 936-949. doi:10.1093/glycob/cwp079
Jenkins, N., Parekh, R. B., & James, D. C. (1996). Getting the
glycosylation right: implications for the biotechnology industry.Nat Biotechnol, 14 (8), 975-981. doi:10.1038/nbt0896-975
Joosten, C. E., & Shuler, M. L. (2003). Effect of culture conditions on
the degree of sialylation of a recombinant glycoprotein expressed in
insect cells. Biotechnol Prog, 19 (3), 739-749.
doi:10.1021/bp0201049
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H. P.,
Miller, D. H., . . . Group, B. S. (2007). Effect of early versus delayed
interferon beta-1b treatment on disability after a first clinical event
suggestive of multiple sclerosis: a 3-year follow-up analysis of the
BENEFIT study. Lancet, 370 (9585), 389-397.
doi:10.1016/S0140-6736(07)61194-5
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P.,
Miller, D. H., . . . Sandbrink, R. (2006). Treatment with interferon
beta-1b delays conversion to clinically definite and McDonald MS in
patients with clinically isolated syndromes. Neurology, 67 (7),
1242-1249. doi:10.1212/01.wnl.0000237641.33768.8d
Karpusas, M., Whitty, A., Runkel, L., & Hochman, P. (1998). The
structure of human interferon-beta: implications for activity.Cell Mol Life Sci, 54 (11), 1203-1216.
Lee, S., Son, W. S., Yang, H. B., Rajasekaran, N., Kim, S. S., Hong, S.,
. . . Shin, Y. K. (2018). A Glycoengineered Interferon-beta Mutein
(R27T) Generates Prolonged Signaling by an Altered Receptor-Binding
Kinetics. Front Pharmacol, 9 , 1568. doi:10.3389/fphar.2018.01568
Madsen, C. (2017). The innovative development in interferon beta
treatments of relapsing-remitting multiple sclerosis. Brain Behav,
7 (6), e00696. doi:10.1002/brb3.696
Mastrangeli, R., Rossi, M., Mascia, M., Palinsky, W., Datola, A.,
Terlizzese, M., & Bierau, H. (2015). In vitro biological
characterization of IFN-beta-1a major glycoforms. Glycobiology,
25 (1), 21-29. doi:10.1093/glycob/cwu082
Morell, A. G., Irvine, R. A., Sternlieb, I., Scheinberg, I. H., &
Ashwell, G. (1968). Physical and chemical studies on ceruloplasmin. V.
Metabolic studies on sialic acid-free ceruloplasmin in vivo. J
Biol Chem, 243 (1), 155-159.
Nam, J. H., Zhang, F., Ermonval, M., Linhardt, R. J., & Sharfstein, S.
T. (2008). The effects of culture conditions on the glycosylation of
secreted human placental alkaline phosphatase produced in Chinese
hamster ovary cells. Biotechnol Bioeng, 100 (6), 1178-1192.
doi:10.1002/bit.21853
Noguchi, A., Mukuria, C. J., Suzuki, E., & Naiki, M. (1995).
Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate
chains of recombinant human erythropoietin expressed in Chinese hamster
ovary cells. J Biochem, 117 (1), 59-62.
doi:10.1093/oxfordjournals.jbchem.a124721
Royle, L., Campbell, M. P., Radcliffe, C. M., White, D. M., Harvey, D.
J., Abrahams, J. L., . . . Dwek, R. A. (2008). HPLC-based analysis of
serum N-glycans on a 96-well plate platform with dedicated database
software. Anal Biochem, 376 (1), 1-12.
doi:10.1016/j.ab.2007.12.012
Royle, L., Radcliffe, C. M., Dwek, R. A., & Rudd, P. M. (2006).
Detailed structural analysis of N-glycans released from glycoproteins in
SDS-PAGE gel bands using HPLC combined with exoglycosidase array
digestions. Methods Mol Biol, 347 , 125-143.
doi:10.1385/1-59745-167-3:125
Sareneva, T., Pirhonen, J., Cantell, K., & Julkunen, I. (1995).
N-glycosylation of human interferon-gamma: glycans at Asn-25 are
critical for protease resistance. Biochem J, 308 ( Pt 1) , 9-14.
doi:10.1042/bj3080009
Sola, R. J., & Griebenow, K. (2010). Glycosylation of therapeutic
proteins: an effective strategy to optimize efficacy. BioDrugs,
24 (1), 9-21. doi:10.2165/11530550-000000000-00000
Song, K., Yoon, I. S., Kim, N. A., Kim, D. H., Lee, J., Lee, H. J., . .
. Shin, Y. K. (2014). Glycoengineering of interferon-beta 1a improves
its biophysical and pharmacokinetic properties. PLoS One, 9 (5),
e96967. doi:10.1371/journal.pone.0096967
van Beers, M. M., Jiskoot, W., & Schellekens, H. (2010). On the role of
aggregates in the immunogenicity of recombinant human interferon beta in
patients with multiple sclerosis. J Interferon Cytokine Res,
30 (10), 767-775. doi:10.1089/jir.2010.0086
Walsh, G., & Jefferis, R. (2006). Post-translational modifications in
the context of therapeutic proteins. Nat Biotechnol, 24 (10),
1241-1252. doi:10.1038/nbt1252
Wright, A., & Morrison, S. L. (1997). Effect of glycosylation on
antibody function: implications for genetic engineering. Trends
Biotechnol, 15 (1), 26-32. doi:10.1016/S0167-7799(96)10062-7
Wurm, F. M. (2004). Production of recombinant protein therapeutics in
cultivated mammalian cells. Nat Biotechnol, 22 (11), 1393-1398.
doi:10.1038/nbt1026
Zhang, S., Li, W., Lu, H., & Liu, Y. (2017). Quantification of
N-glycosylation site occupancy status based on labeling/label-free
strategies with LC-MS/MS. Talanta, 170 , 509-513.
doi:10.1016/j.talanta.2017.04.053